LabCorp buys National Genetics Institute:
This article was originally published in Clinica
Executive Summary
Laboratory Corporation of America (LabCorp) has agreed to buy all of the stock of National Genetics Institute, a privately held provider of molecular diagnostic hepatitis C (HCV) testing. Terms of the agreement, which is expected to close in July, were not disclosed. LabCorp says the deal with Los Angeles-based National Genetics will bring it ultra-sensitive tools to assess HCV disease progress at reviously undetectable levels. We believe infectious disease testing, and specifically hepatitis C testing employing molecular diagnostics, will continue to be one of the fastest growing areas of laboratory testing," said Thomas MacMahon, LabCorp's CEO.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.